Compare VFL & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFL | SGHT |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.7M | 193.2M |
| IPO Year | N/A | 2021 |
| Metric | VFL | SGHT |
|---|---|---|
| Price | $10.19 | $8.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $6.66 |
| AVG Volume (30 Days) | 38.0K | ★ 180.1K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,052,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.93 | $2.03 |
| 52 Week High | $10.77 | $8.80 |
| Indicator | VFL | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 55.35 | 60.36 |
| Support Level | $10.08 | $8.22 |
| Resistance Level | $10.26 | $8.63 |
| Average True Range (ATR) | 0.08 | 0.51 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 75.86 | 58.85 |
abrdn National Municipal Income Fund is a closed-end investment fund. The Fund's investment objective is to seek to provide current income exempt from regular federal income tax, consistent with the preservation of capital. The company's product portfolio includes Mutual funds, Exchange-traded funds, Private markets, Delaware Funds by Macquarie Premier Models, Managed accounts, Closed-end funds, and Variable Insurance Products.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.